Targeted DNA RNA Sequencing Market Size, Share & Trends Analysis Report By Product (NGS), By Workflow (Pre-sequencing), By Application, By Technology, By Type, By End Use, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global targeted DNA RNA sequencing market size was valued at USD 10.12 billion in 2023 and is projected to grow at a CAGR of 19.4% from 2024 to 2030. DNA and RNA sequencing enables the precise sequence of nucleotides in DNA or RNA molecules, which is critical to understanding genetic information and biological functions the target DNA/RNA structure focuses on specific genes or regions, increasing the accuracy of diagnosis and personalized treatment.

With the rising incidences of diseases such as cancer, heart diseases, and genetic disorders the need to diagnose and develop specific treatments drives the market growth. In targeted sequencing, it is possible to find the pathogenic variation at a comparatively earlier point in the process, which diagnoses and improves treatment options. This is particularly sensitive if the cancer type can be treated with targeted therapy that may not cause as many side effects as chemotherapy.

The market development can be attributed to the introduction of Next Generation (NGS) technology. This method improves quantification by providing read counts of specific molecular identifiers bound to DNA molecules before amplification, rather than counting all reads. In addition, genetic testing has increased the data set, allowing researchers, clinicians, and patients to better understand genetic susceptibility to specific diseases. The market for DNA/RNA sequencing is growing due to technological advances, cost reductions, and increasing demand for personalization and precision medicine in oncology and rare diseases.

Product Insights

The next generation sequencing (NGS) segment dominated the market in 2023 pertaining to the offering of NGS technology with several advantages over older methods, including the ability to sequence a much larger number of targets simultaneously and at a significantly lower cost. These factors highlight the significance of NGS, which is the most widely used workflow in targeted sequencing by all researchers and healthcare service providers in the market.

The others segment is projected to grow at a substantial rate over the forecast period. This segment extends to other fields apart from drug discovery, human health, and plant & animals as highlighted below. The emergence of research branches such as pharmacogenomics deals with the impact of genes on the effectiveness of drugs, and metagenomics, which is focused on determining the genomes of microbes in an environment. This has unveiled new opportunities for targeted sequencing in tools, thus stimulating segment growth.

Workflow Insights

The sequencing segment dominated the market in 2023. The dominance majorly highlights its role in every stage of the process. The sequencing segment defines the particular order of nucleotides in the targeted DNA or RNA, which creates the basis for all other analyses contributing to the market growth.

The pre-sequencing segment is projected to grow at a substantial rate over the forecast period. This is due to pre-sequencing aspects, for instance, library preparation and target enrichment is more efficient and specific in isolating the required areas. Secondly, due to the increasing need for high-throughput sequencing, there is a higher requirement for the pre-sequencing processes for large samples.

Application Insights

Drug discovery dominated the market and accounted for a share of 42.5% in 2023. This is attributed to the pharmaceutical companies that target sequencing to determine genetic factors that are related to specific diseases. Additionally, it accelerates drug development by concentrating on targets and guarantees the formation of more efficient medicines with fewer side effects. With the increasing focus on personalized medicine, targeted sequencing has become an invaluable tool for drug development tailored to individual patient needs, further propelling its growth.

Plant and animal sciences are expected to register a CAGR of 19.9% during the forecast period. This is due to the agriculture sector which makes it possible to determine genes associated with the desired characteristics in plants and animals. Additionally, in animal breeding, targeted sequencing assists in selecting animals with superior traits leading to improved livestock quality and productivity. Veterinary medicine is widely applied in targeted sequencing to identify diseases that affect animals and formulate individual treatment plans.

Type Insights

The DNA based targeted sequencing segment dominated the market in 2023. This is due to DNA analysis offering a more stable target compared to RNA, which degrades faster. This stability allows convenience in sample handling, storage, and analysis. Targeted DNA sequencing is enhanced by its precise drug compatibility. By targeting specific genes associated with diseases, researchers can develop personalized therapies. Furthermore, DNA sequencing is a more advanced technology than RNA, providing a faster and more cost-effective workflow.

The RNA based targeted sequencing segment is projected to grow at a substantial rate over the forecast period. The newer methods aimed at stabilizing RNA are helping to overcome the basic problem of RNA instability, making RNA less risky to target. Additionally, RNA sequencing provides a dynamic view of gene expressional analysis in the cellular processes and mechanisms in the development of diseases drives market growth.

End Use Insights

The academic research segment dominated in 2023 due to its vital role in driving scientific discoveries. Using custom research, researchers can identify specific genes or regions for in-depth analysis, allowing them to explore specific research questions in more detail. Additionally, targeted sequencing offers a powerful tool for uncovering new disease mechanisms. By efficiently identifying genetic variants, researchers can gain important insights into how diseases develop and progress, paving the way for future breakthroughs.

The pharma and biotech entities segment is projected to grow at a CAGR of 20.1% over the forecast period. They are more effective because targeted sequencing helps to identify each key component specifically related to diseases. Secondly, it shortens drug development timelines as researchers avoid irrelevant pathways, hence allowing patients to access new drugs in the shortest time possible.

Regional Insights

North America targeted the DNA RNA sequencing market and accounted for largest revenue share of 41.50% in 2023 owing to the region being home to many well-resourced research organizations and implementing pharma organizations, which have expressed a very high interest in using this technology to aid drug discovery and development. Additionally, North America has the appropriate legal framework and high disposable incomes, and targets sequencing for a broad application in diagnosis and personal approaches in the healthcare field.

U.S. Targeted DNA RNA Sequencing Market Trends

The U.S. targeted DNA RNA sequencing market dominated North America with a share of 87.3% in 2023 due to a significant rise in government funding for research and policies, besides a rich pool of the biotech and pharma industry and research universities. Furthermore, investment and expertise enhance the advancement and utilization of the targeted sequencing across different areas.

Europe Targeted DNA RNA Sequencing Market Trends

Europe targeted DNA RNA sequencing market was identified as a lucrative region in 2023. This growth is fueled by governmental support for genomics research and more attention paid to personalized medicine programs. Based on these factors the market players and researchers have a conducive environment to increase the use of targeted sequencing technologies in Europe.

UK targeted DNA RNA sequencing market is expected to grow rapidly in the coming years due to a solid academic foundation of genomics in the UK, and some research facilities are already applying genomics in medical research. Secondly, government-related schemes such as the 100,000 Genomes Project and the infrastructure in genomics are promoting the adoption of targeted sequencing in the UK healthcare system.

Asia Pacific Targeted DNA RNA Sequencing Market Trends

Asia Pacific targeted DNA RNA sequencing market is anticipated to witness significant growth. This surge is driven by the increase in disposable income and rising government expenditure in genomics. These factors have created more demand in the healthcare sector and unlocked new opportunities for sequencing technologies for diagnostics and personalized medicine in the regional market.

China targeted DNA RNA sequencing market held a substantial market share in 2023 due to a steady rise in the population to advance a massive demand for superior medical services. Additionally, the government policies drive the local industries to develop and increase access to targeted sequencing systems for research and diagnostics.

Key Targeted DNA RNA Sequencing Company Insights

Some key companies in the global targeted DNA RNA sequencing market include Illumina, F. Hoffman La-Roche Ltd, QIAGEN, Bio-Rad Laboratories, and others. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players undertake several strategic initiatives, such as mergers, acquisitions, and partnerships with other major companies. 

• Illumina is among the world’s foremost makers of genomic equipment including DNA sequencing and microarray technology. Their products assist researchers and healthcare providers with information that can be used to diagnose diseases, develop individualized treatments, and progress various scientific disciplines related to genetics.

• Roche is a leading healthcare company, dedicated to research and innovation in pharmaceutical and diagnostic products. They own leading clinical products in oncology, immunology, and diagnostic products for personalized medicine.

Recent Developments

• In June 2024, Bio-Rad launched a new ddSEQ Single-Cell 3' RNA-Seq Kit to support single-cell gene expression research. This kit enables researchers to affordably and rapidly analyze gene expression on the single-cell resolution. It is anticipated that this technology will help in the research of oncology, immunology, and more.

• In May 2024, a new paper was published in Genomic Medicine highlighting global efforts to increase access to genome sequencing for diagnosing rare genetic disorders and focusing on its potential to improve diagnosis speed and reduce healthcare costs. The Medical Genome Initiative calls for broader insurance coverage, reduced administrative barriers, and increased clinician education to support the widespread adoption of genome sequencing.

Targeted DNA RNA Sequencing Market Report Scope

Global Targeted DNA RNA Sequencing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global targeted DNA RNA sequencing market report based on product, workflow, application, type, end use, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • NGS

    • Method

      • Exome Sequencing

      • Enrichment Sequencing

      • Amplicon Sequencing

      • Others

    • Application

      • Cancer Gene Sequencing

      • Inherited Disease Screening

      • Drug Development

      • Forensic Genomics

      • 16S ribosomal RNA (rRNA) sequencing

  • Others

• Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Pre-sequencing

  • Sequencing

  • Data Analysis

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Human Biomedical Research

  • Plant & Animal Sciences

  • Drug Discovery

  • Others

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • DNA Based Targeted Sequencing

  • RNA Based Targeted Sequencing

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Academic Research

  • Hospitals & Clinics

  • Pharma & Biotech Entities

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait